This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

43/100

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Inflammation and the immune system

Topic: Brain proteins, microglia and lab models

Plain-language summary

Vascular cognitive impairment and dementia (VCID) is increasingly recognized as one of the leading causes of cognitive decline in aging populations. VCID is driven by the interplay of endothelial dysfunction, chronic inflammation, oxidative stress, and metabolic dysregulation. Aging exacerbates cerebrovascular damage by impairing endothelial function, compromising the blood-brain barrier (BBB), and promoting neuroinflammation, all of which contribute to the progression of small vessel disease (SVD) and white matter hyperintensities (WMHs), which are hallmarks of VCID. Epidemiological evidence suggests that aging is associated with modifications in circulating low-density lipoprotein (LDL) and high-density lipoproteins (HDL), particularly oxidation, which further accelerates neurovascular pathology. Oxidized LDL (oxLDL) disrupts endothelial homeostasis, enhances leukocyte adhesion, and triggers chronic inflammatory signaling through microglial and astrocytic activation. Additionally, oxLDL-mediated oxidative stress exacerbates mitochondrial dysfunction and epigenetic alterations in cerebrovascular cells, reinforcing a cycle of vascular injury and neurodegeneration. These mechanisms contribute to neurovascular uncoupling, cerebral hypoperfusion, and cognitive decline in aging individuals. This review examines the pathophysiological role of oxLDL in VCID, with a focus on its impact on endothelial integrity, BBB function, neuroinflammation, and lipid-mediated neurodegenerative processes. Furthermore, we discuss emerging therapeutic strategies targeting LDL oxidation, inflammation, and endothelial dysfunction as potential interventions to mitigate the burden of VCID in aging populations.

What this study adds

Evidence grade: Low

This review discusses how oxidized LDL may contribute to blood vessel damage, inflammation and cognitive decline in vascular cognitive impairment and dementia. It outlines mechanisms rather than testing a treatment.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ihuoma, J., Milan, M., Negri, S., Troyano‐Rodriguez, E., Rudraboina, R., Kosmider, A., et al. (2026). LDL oxidation and cerebrovascular aging: mechanisms of endothelial dysfunction, inflammation, and vascular cognitive impairment and dementia. Redox Biology. https://doi.org/10.1016/j.redox.2026.104118

Vancouver

Ihuoma J, Milan M, Negri S, Troyano‐Rodriguez E, Rudraboina R, Kosmider A, et al. LDL oxidation and cerebrovascular aging: mechanisms of endothelial dysfunction, inflammation, and vascular cognitive impairment and dementia. Redox Biology. 2026. doi:10.1016/j.redox.2026.104118. PMID: 41831270.

BibTeX

@article{ihuoma2026-41831270,
  author  = {Ihuoma, Jennifer and Milan, Madison and Negri, Sharon and Troyano‐Rodriguez, Eva and Rudraboina, Rakesh and Kosmider, Aleksandra and Awasthi, Shantipriya and Csiszar, Anna and others},
  title   = {{LDL oxidation and cerebrovascular aging: mechanisms of endothelial dysfunction, inflammation, and vascular cognitive impairment and dementia}},
  journal = {Redox Biology},
  year    = {2026},
  doi     = {10.1016/j.redox.2026.104118},
  pmid    = {41831270},
  url     = {https://doi.org/10.1016/j.redox.2026.104118}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Epidemiological evidence suggests that aging is associated with modifications in circulating low-density lipoprotein (LDL) and high-density lipoproteins (HDL), particularly oxidation, which further accelerates neurovascular pathology.

Why it matters

Study details

Evidence strengthLow

How this study scored 43/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Redox Biology)
Journal's citation record	2 / 4	Redox Biology: journal h-index 209 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	2 / 7	Cited 12 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	6.0 citations a year over 2 year(s) since 2026
Impact for its field and year	5 / 6	Cited 30.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Stefano Tarantini: h-index 63 (OpenAlex, whole career)
Institution's track record	0 / 3	University of Oklahoma Health Sciences Center: institution h-index 557 (OpenAlex)
Multicenter collaboration	1 / 3	OpenAlex lists 3 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41831270)
Free to read	2 / 2	Free to read
Total	43 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Inflammation and the immune system from nearby years

Also tagged “small”

900 studies in the library carry the topic tag “small”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →